Citadel Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-14,802
| Closed | -$9.35K | – | 15795 |
|
|
2024
Q3 | $9.35K | Buy |
+14,802
| New | +$14.7K | ﹤0.01% | 13264 |
|
|
2023
Q4 | – | Sell |
-1,958
| Closed | -$9.45K | – | 15687 |
|
|
2023
Q3 | $9.45K | Sell |
1,958
-1,689
| -46% | -$12K | ﹤0.01% | 13125 |
|
|
2023
Q2 | $46.7K | Buy |
+3,647
| New | +$71.9K | ﹤0.01% | 11879 |
|
|
2022
Q4 | – | Sell |
-162
| Closed | -$19K | – | 15697 |
|
|
2022
Q3 | $19K | Buy |
+162
| New | +$26.9K | ﹤0.01% | 12099 |
|
|
2021
Q4 | – | Sell |
-144
| Closed | -$96.5K | – | 15105 |
|
|
2021
Q3 | $116K | Buy |
+144
| New | +$162K | ﹤0.01% | 12688 |
|
|
2021
Q2 | – | Sell |
-114
| Closed | -$156K | – | 14673 |
|
|
2021
Q1 | $159K | Buy |
114
+89
| +356% | +$119K | ﹤0.01% | 11974 |
|
|
2020
Q4 | $26K | Buy |
+25
| New | +$16.1K | ﹤0.01% | 10738 |
|
|
2019
Q1 | – | Sell |
-3
| Closed | -$11K | – | 10055 |
|
|
2018
Q4 | $11K | Sell |
3
-4
| -57% | -$20.4K | ﹤0.01% | 8916 |
|
|
2018
Q3 | $21K | Buy |
+7
| New | +$18.4K | ﹤0.01% | 9000 |
|
|
2018
Q2 | – | Sell |
-3
| Closed | -$45K | – | 9421 |
|
|
2018
Q1 | $45K | Buy |
+3
| New | +$80.3K | ﹤0.01% | 7956 |
|
|
2017
Q4 | – | Hold |
0
| – | -$15K | – | 8569 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7411 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7351 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7244 |
|
|
2016
Q4 | – | Hold |
0
| – | -$18K | – | 8011 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7085 |
|
Other funds holding CYTO
Citadel Advisors's CYTO Position: Q4 2024 in Review
Citadel Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2024, closing a stake of 14,802 shares — an estimated $9.35K sold.
Citadel Advisors first reported a position in CYTO in Q1 2018 and held it in 10 quarters. The position peaked at $159K in Q1 2021. 2 funds tracked by Wall St. Rank hold CYTO as of Q4 2024.
- Citadel Advisors reported no remaining Altamira Therapeutics Ltd position as of Q4 2024 after selling out during the quarter.
- Citadel Advisors sold 14,802 Altamira Therapeutics Ltd shares in Q4 2024, an estimated $9.35K.
- Citadel Advisors first reported a position in Altamira Therapeutics Ltd in Q1 2018 and held it in 10 quarters.
- Citadel Advisors's Altamira Therapeutics Ltd position peaked at $159K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2024.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.